The impact of repeated cost containment policies on pharmaceutical expenditure: Experience in Spain

European Journal of Health Economics

Volumn 12, Issue 6, 2011, Pages 563-573

  Moreno Torres, Iván ^a   Puig Junoy, Jaume ^a   Raya, Josep M ^a  

^a DEPARTMENT OF ECONOMICS AND BUSINESS   (Spain)

Author keywords

Cost containment measures; Pharmaceutical expenditure; Pharmaceutical policy; Time series

Indexed keywords

ARTICLE; AUTOREGRESSIVE INTEGRATED MOVING AVERAGE; COST CONTROL; DEVELOPED COUNTRY; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; HEALTH CARE POLICY; ORGANIZATION AND MANAGEMENT; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE PRICING; PUBLIC HEALTH; SPAIN; TIME SERIES ANALYSIS;

COST CONTROL; DRUG COSTS; DRUG INDUSTRY; DRUG PRESCRIPTIONS; ECONOMICS, PHARMACEUTICAL; GOVERNMENT REGULATION; HEALTH EXPENDITURES; HEALTH POLICY; HUMANS; PHARMACEUTICAL PREPARATIONS; PUBLIC HEALTH; SPAIN;

EID: 80455132183     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-010-0271-1     Document Type: Article

References (19)

1. N Sood H de Vries I Gutierrez, et al. 2009 The effect of regulation on pharmaceutical revenues: Experience in nineteen countries Health Aff. 28 w125 w137 10.1377/hlthaff.28.1.w125
2. F Antoñanzas J Oliva M Pinillos C Juárez 2007 Economic aspects of the new Spanish laws on pharmaceutical preparations Eur. J. Health Econ. 8 297 300 17401592 10.1007/s10198-007-0050-9 (Pubitemid 47231316)
3. J Costa-Font J Puig-Junoy 2005 The pharmaceutical market regulation in Spain: is drug cost-containment under question? J. Pharma. Fin., Econ. Policy 13 33 49 10.1300/J371v13n04-04
4. J Puig-Junoy 2004 Incentives and pharmaceutical reimbursement reforms in Spain Health Policy 67 149 165 14720633 10.1016/S0168-8510(03)00113-1 (Pubitemid 38068213)
5. JR Borrell 2003 Drug price differentials caused by formularies and price caps Int. J. Econ. Bus. 10 37 50 10.1080/1357151032000043311
6. J Puig-Junoy I Moreno-Torres 2007 Impact of pharmaceutical prior authorisation policies: a systematic review of the literature Pharmacoeconomics 25 637 648 17640106 10.2165/00019053-200725080-00002 (Pubitemid 47124166)
7. P Kanavos J Costa-Font E Seeley 2008 Competition in off-patent drug markets: Issues, regulation and evidence Econ. Policy 23 499 544 10.1111/j.1468-0327.2008.00207.x
8. YC Lee MC Yang YT Huang, et al. 2006 Impacts of cost containment strategies on pharmaceutical expenditures of the national health insurance in Taiwan, 1996-2003 Pharmacoeconomics 24 891 902 16942123 10.2165/00019053- 200624090-00006 (Pubitemid 44338299)
9. GEP Box GC Tiao 1975 Intervention analysis with applications to economic and environmental problems J. Amer. Stat Assoc. 70 70 79 10.2307/2285379
10. Box, G.E.P., Jenkins, G.M., Reinsel, G.C.: Time Series Analysis: Forecasting and Control, 3rd edn. Prentice Hall, Upper Saddle River, NJ (1994)
11. Enders, W.: Applied Econometric Time Series. Wiley cop, New York (1995)
12. V Atella 2000 Drug cost containment policies in Italy: are they really effective in the long-run? The case of minimum reference price Health Policy 50 197 218 10827308 10.1016/S0168-8510(99)00070-6 1:STN:280: DC%2BD3M%2FgsFejug%3D%3D (Pubitemid 30072736)
13. NK Choudhry B Zagorski J Avorn, et al. 2008 Comparison of the impact of the atrial fibrillation follow-up investigation of rhythm management trial on prescribing patterns: a time-series analysis Ann. Pharmacother. 42 1563 1572 18827174 10.1345/aph.1L211
14. L Blais J Couture E Rahme, et al. 2003 Impact of a cost sharing drug insurance plan on drug utilization among individuals receiving social assistance Health Policy 64 163 172 12694953 10.1016/S0168-8510(02)00158-6 (Pubitemid 36407673)
15. D Marshall J Gough P Grootendorst, et al. 2006 Impact of administrative restrictions on antibiotic use and expenditure in Ontario: time series analysis J Health Serv. Res. Policy 11 13 20 16378528 10.1258/135581906775094253 (Pubitemid 43117108)
16. M Ong R Catalano T Hartig 2003 A time-series analysis of the effect of increased copayments on the prescription of antidepressants, anxiolytics, and sedatives in Sweden from 1990 to 1999 Clin. Ther. 25 1262 1275 12809972 10.1016/S0149-2918(03)80082-6 (Pubitemid 36532593)
17. GEP Box DA Pierce 1970 Distribution of residual autocorrelations in autoregressive-integrated moving average time series models J. Amer. Stat Assoc. 65 1509 1526 10.2307/2284333
18. MC Gemmill J Costa-Font A McGuire 2007 In search of a corrected prescription drug Elasticity estimate: a meta-regression approach Health Econ. 16 627 643 17238227 10.1002/hec.1190 (Pubitemid 46915882)
19. J Darbà 2003 Pharmaceutical expenditure in Spain: Evolution and cost containment measures during 1998-2001 Eur. J. Health Econ 4 151 157 15609181 10.1007/s10198-003-0167-4 (Pubitemid 37247967)